In recent years, the immunotherapy field has revolutionized oncology treatment methods by developing therapeutics that help a cancer patient’s own immune system fight their disease.
However, these treatments have had varied efficacies in different cancer types.
Although immunotherapy has become the standard therapeutic method for fighting liver cancer, also called hepatocellular carcinoma (HCC), its response rate has only been approximately 30% in patients with advanced disease.
In a recent article published in Hepatology, a team led by researchers at Osaka University developed an analytical method that could help predict if an HCC patient would successfully respond to immunotherapy.
The tumour immune microenvironment (TIME) is the area inside the tumour in which various immune cells and other cell types interact and send/receive messages and signals.
Within the TIME, the presence of tumour-infiltrating lymphocytes, one type of white blood cells, is critical because they can recognize tumour cells and help fight them.
Additionally, expression levels of immune checkpoint proteins are also important, because these are targets of many immunotherapy drugs. Therefore, the Osaka University group aimed to examine and characterize the TIMEs of various HCC patients to identify immunotherapy-susceptible cases.
“We examined 113 patients that developed HCC without hepatitis virus infection,” says Hiroki Murai, lead author of the study.
“We used a multi-omics approach, meaning we examined the DNA sequences of specific genes frequently mutated in HCC, but also performed a more general assessment of RNA sequences to investigate expression levels of all genes in these tumours.”
Using this workflow, the team categorized the 113 HCC cases based on their TIME composition estimated by gene expression profile.
The TIME is commonly labeled as immune-excluded, immune-active, or immune-exhausted. Interestingly, they found a unique TIME in 23% of the HCC cases that had a significant amount of intra-tumoural fat accumulation, known as steatotic HCC.
“Steatotic HCC tumours tended to have an immune-enriched, but immune-exhausted TIME,” explains senior author Tetsuo Takehara.
“There was high infiltration of immune cells, including M2 macrophages and cancer-associated fibroblasts, but the nearby T cells were exhausted. They lost much of their fighting ability.”
The group also determined that the increased fat levels in these tumour cells induced expression of PD-L1, an immune checkpoint molecule that leads to an immunosuppressive TIME.
“PD-L1 is a common target of immunotherapy drugs because interfering with this protein can help restore the functions of the immune cells,” says Takahiro Kodama, co-lead author of the study.
“Our findings suggest that HCC tumours with steatosis would therefore be susceptible to these types of drugs.”
Searching for a non-invasive identification system, the authors found that MRI scans could be used to identify steatotic HCC patients who may be susceptible to a combined immunotherapy approach.
The data presented in this work are therefore important in that they demonstrate that intratumour steatosis could be used as a novel biomarker for evaluating immunotherapy efficacy in HCC cases.
Image Credit: Takahiro Kodama
Source: Osaka University
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.